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Summary. One hundred and eighty-one consecutive patients 
with standard-risk leukaemia were transplanted with HLA- 
identical sibling grafts depleted of lymphocytes using counter­
flow centrifugation. In 116 patients, standard conditioning 
was intensified by the addition of anthracyclines.
Multivariate analysis revealed significantly more acute 
GVHD ^  grade 2 and a trend towards more chronic GVHD 
in patients conditioned with the addition of anthracyclines. 
For all patients the risk for chronic GVHD, but not for acute 
GVHD, increased with a higher number of T cells in the graft. 
The projected 5-year probability of relapse was significantly 
lower in the group of patients conditioned with anthracy­
clines; 26% versus 52% (P =  0*015). In multivariate analysis 
the addition of anthracyclines to the conditioning regimen 
was the only significant factor contributing to a lower 
probability of relapse. The projected 5-year probability of 
leukaemia-free survival [LFS] in the patients conditioned
with and without the addition of anthracyclines was 56% 
and 36%, respectively (P =  0-004). In multivariate analysis 
the addition of anthracyclines to the conditioning regimen 
correlated significantly with a lower number of mixed 
chimaeras in patients at 6 and 12 months after BMT. 
Mixed chimaerism at 6 months after transplantation did not 
significantly correlate with a higher incidence of relapse in 
further follow-up. In contrast, mixed chimaerism at 12 
months after BMT was significantly associated with higher 
relapse rate.
We conclude that the addition of anthracyclines to the 
conditioning regimen improves outcome of BMT using T- 
cell-depieted grafts.
Keywords: allogeneic bone marrow transplantation, T-cell 
depletion, standard-risk leukaemia, anthracyclines, 
chimaerism.
Allogeneic bone marrow transplantation (BMT) is an 
effective consolidation treatment for patients in complete 
remission from acute leukaemia or lymphoblastic lymphoma 
(Chao et al, 1991; De Witte et al, 1994; Jourdan et al, 1995; 
Ringden et al, 1987; Stockschlader et al, 1995; Zittoun et al, 
1995). In chronic myeloid leukaemia, myelodysplastic 
syndrome and low-grade non-Hodgkin’s lymphoma, BMT 
is the only curative treatment (Anderson et a!, 1995; Clift et 
al, 1993; De Witte & Gratwohl, 1993; Goldman et al, 1988; 
Gratwohl et al, 1993; Lazarus, 1995). Allogeneic BMT 
appears to be the most promising treatment for multiple 
myeloma (Gahrton et al, 1995; Gahrton, 1996). Major 
complications after BMT are acute and chronic graft-versus- 
host disease (GVHD). Moderate to severe GVHD occurs in
Correspondence: Dr Nicolaas P. M. Schaap, Division of Haematology, 
University Hospital Nijmegen. Geert Grooteplein Zuid 8, 6525 GA 
Nijmegen, The Netherlands.
about 45% of recipients of HLA-identical marrow grafts and 
contributes to death in 20-70%  of those affected (Apperley 
et al, 1986; Butturini & Gale, 1988; De Witte et al, 1984; 
Glucksberg et al, 1974; Goldman et al, 1988; Plas et al, 1988; 
Schattenberg et al, 1990). Reduction of GVHD can be 
accomplished by T-cell depletion of the graft. However, the 
removal of immunocompetent T lymphocytes is associated 
with increased graft rejection and increased relapse rate 
(Apperley et al, 1986; Butturini & Gale, 1988; Goldman et al, 
1988; Maraninchi et al, 1987; Marmont et al, 1991). We 
have previously reported the outcome of 80 consecutive 
patients transplanted for acute and chronic leukaemia with 
HLA-identical sibling grafts depleted of lymphocytes by 
counterflow centrifugation. We concluded that the prob­
ability of survival and leukaemia-free survival (LFS) was 
comparable with the data of recipients of unmanipulated 
grafts (Schattenberg et al, 1990). In the present analysis we 
extended our observations to 181 consecutive
750 © 1997 Blackwell Science Ltd
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transplanted for standard-risk acute and chronic leukaemia 
between 1981 and 1995. This is one of the largest groups of 
patients described in the literature transplanted with T-ceII- 
depleted marrow grafts from a single centre. Median follow- 
up was 5-5 years (range 3 months to 14 years). The longer 
median follow-up and the higher number of patients enabled 
us to address the issues of sustained engraftment, acute and 
chronic GVHD, the impact of intensification of the con­
ditioning regimen by the addition of anthracyclines, the 
influence of the number of T lymphocytes infused within the 
graft, chimaerism, transplantation-related mortality, leu- 
kaemic relapse, long-term survival and LFS.
MATERIALS AND METHODS
Patients and donors. Between May 1981 and September 
1995, 181 consecutive patients (105 males and 76 females) 
received a transplant for acute myeloid leukaemia in first 
complete remission (AML-CR1: n = 7 0), acute lymphoid 
leukaemia in first and second complete remission (ALL-CR1, 
CR2: n =  57) and chronic myeloid leukaemia in first chronic 
phase (CML-CP1: n =  54). Donors were HLA-identical and 
MLC-negative siblings. Median age of the recipients and the 
donors was 34 (range 13 -59) and 35 (range 1 1 -7 1 ) years, 
respectively. Informed consent was obtained from all 
recipients and donors or their guardians. Donor marrow 
was depleted of lymphocytes by density gradient centrifuga­
tion followed by counterflow centrifugation as previously 
described (De Witte et al, 1984; Plas et al, 1988). The median 
number of T cells infused was 0-8 (range 0-1-3-2) x 10f7kg 
body weight. All patients were managed in single rooms with 
filtered air under positive pressure during their hospital stay. 
All patients received oral selective gut decontamination, as 
well as co-trimoxazole for Pneumocystis carinii prophylaxis 
and oral acyclovir for prophylaxis of herpes virus infections. 
The patient's characteristics are summarized in Table I.
Chemotherapy before allografting. All patients with CML had 
been treated with hydroxyurea or busulphan. In three 
patients interferon alpha was added. Patients with ALL and 
AML were in CR1 or CR2 after chemotherapy according to 
current EORTC (European Organization for Research and 
Treatment of Cancer) protocols.
Conditioning regimen. All patients were treated with 
cyclophosphamide (Cy) (60 mg/kg body weight) intra­
venously (i.v.) on days —6 and —5. Fractionated total body 
irradiation (TBI) was given to 174 patients in two equal 
fractions on days —2 and —1 to a total dose of either 9 Gy 
(n =  143) or 12 Gy (n =  31). Midline average dose rate was 
4-1 ± 0 -5  cGy/min in 33 patients and 12-3 ± 2 -0  cGy/min 
in 141 patients. TBI was delivered by a 16 or 18 MV photon 
beam linear accelerator. Lungs and eyes were shielded to 7 or 
8 Gy and 6 Gy, respectively, using individually adapted lead 
blocks. If the total dose was 12 Gy, the kidneys were shielded 
to 9 Gy. In an attempt to reduce relapse rate, the 
conditioning regimen was intensified in 116 patients by 
the addition of daunorubicine to a total dose of 15 6 mg/m2 
body surface (n = 1 0 ) or demethoxy-daunorubicine (ida- 
rubicine) to a total dose of 42 mg/m2 body surface (n =  106)
(Muus et al, 1992; Raemaekers et al, 1989). Anthracyclines 
were given by continuous i.v. infusion for 2 -7  d. However, 
the first cohort patients treated with anthracyclines showed 
significantly more severe oral mucositis and and delayed 
bone marrow recovery (Muus et al, 1993). In the next cohort 
TBI was increased to 2 x 6  Gy and no anthracyclines were 
given. This resulted in a high 5-year probability of relapse of 
57% (95% Cl 37-77%). Since oral mucositis and delayed 
engraftment were schedule dependent, anthracyclines were 
reintroduced from February 1991 onwards and given on day 
—.11 and —12 instead of day —7 to - 2  in combination with 
2x4*5 Gy TBI. In seven recipients TBI was replaced by 
busulphan (4 mg/kg/d on each of 4 consecutive days). The 
donor marrow was infused 2 4 h after completion of TBI or 
72 h after the last dose of busulphan.
Immunoprophylaxls after transplantation. Details of iminuno- 
prophylaxis post-transplant have been described (Schatten- 
berg et al, 1990). Two patients did not receive any GVHD 
prophylaxis and both developed grade 3 acute GVHD. Eight 
patients received methotrexate (MTX). As soon as Cyclo- 
sporine A (CsA) became available, 22 consecutive recipients 
received MTX in combination with CsA. From May 1986 
onwards all patients (n =  149) were treated with CsA only; 
3 mg/kg/d by continuous i.v. infusion from days —1 to +14, 
followed by 2 mg/kg/d as a continuous i.v. infusion until day 
21. Beyond day 21, CsA was administered orally at a dose of 
6 mg/kg/d until 12 weeks after BMT. CsA was gradually 
tapered and discontinued 16 weeks postgrafting.
Acute and chronic GVHD were classified grade 1 -4  and 
limited or extensive, respectively, according to the criteria 
described by Glucksberg et al (1974) and Shulman et al
Definitions. Engraftment: the first day of engraftment was 
defined as the first of 3 consecutive days with peripheral 
white blood cell (WBC) counts of ^  1*0 x l()l,/l. Graft failure 
was defined as primary if the WBC never reached 1*0 x 109/1 
or secondary if the WBC reached l-()x l()<Vl on 3 or more 
consecutive days and disappeared during further follow-up. 
Transplant-related mortality was defined as mortality not 
due to relapse. Relapse was defined as haematological 
relapse, i.e. the reappearance of clinical features and 
laboratory findings compatible with the underlying leukae­
mia. LFS survival was defined as survival in haematological 
or haematological and cytogenetic remission.
Statistical analysis. Probability of relapse, survival, LFS,
aerism on subsequent relapserC
Kaplan-Meier pr 
method. The differences between curves were tested for 
statistical significance with the two-tailed log-rank test. To 
determine whether diagnosis, recipient age, recipient sex, 
donor age, donor sex, chemotherapy before allografting, 
conditioning regimen, T-cell dose and GVHD prophylaxis 
were independent predictors of relapse, survival, leukaemia- 
free survival, acute GVHD, chronic GVHD and chimaerism, 
multivariate stepwise regresssion analysis was performed 
using Cox’s proportional hazard 
regression. P values <0*05 were c 
Follow-up ended on 1 January 1996, Survival and relapse 
were followed to the time of last contact with the patient.
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Table I. Disease-, patient-, donor-, and treatment-related variables of 181 patients transplanted for acute 
and chronic leukaemia with and without the addition of anthracyclines in the conditioning regimen.
Conditioned with 
anthracyclines
Conditioned without 
anthracyclines
Diagnosis, no. (%) of patients
AML, CR1 41 (23) 29 (16)
CML, CP 1 40 (22) 14 (8)
30 (16) 8 (10)
ALL, CR2 5 (3 ) 4 (2 )
No. (%) of male/female patients 71 (39)/45 (25) 34 (19)/31 (17)
No. (%) of male/female donors 64 (35)/52 (29) 44 (24)/21 (12)
Donor-recipient sex match, no. and (%) of patients
Male to male 37 (20) 30 (17)
Male to female 27 (.15) 11 (6)
Female to male 3 3 (1 8 ) 9 (5)
Female to female 19 (11) 15 (8)
Age patients, median (range) in years 36 (13 -59 ) 32 (16-55)
Age donors, median (range) in years 37 (11 -71 ) 32 (16-59)
Conditioning regimen, no. and (%) of patients
Cyclophosphamide, TBI 110 (61) 64 (35)
Cyclophosphamide, busulphan 6 (3 ) 1 (1)
Graft-versus-host prophylaxis, no. and (%) of patients
Cyclosporine A 116 (64) 33 (18)
Cyclosporine A plus methotrexate 0 (0) 22 (12)
Methotrexate 0 (0 ) 8 ( 5)
None 0 (0 ) 2 ( 1 )
No. of T cells in graft, median (range) x 10r7kg 0-9 (0-1-3-2) 0-7 (0-2-2-7)
Follow-up, median (range) in years 3-8 (0-3-9-5) 5-6 (4-0-14)
Abbreviations: AML, acute myeloid leukaemia; ALL, acute lymphoid leukaemia; CML, chronic myeloid 
leukaemia; CR1, first complete remission; CR2, second complete remission; CPI, first chronic phase; 
TBI, total body irradiation.
RESULTS
Engraftment
Six patients died within 22 d after BMT and were not 
evaluable for engraftment. Graft failure occurred in 4 /114  
evaluable patients (3%) after conditioning with anthra- 
cyclines and in 4 /61 evaluable patients (7%) conditioned 
with the standard regimen. In both groups one patient never 
showed any sign of engraftment (primary graft failure). 
Another six patients rejected their graft (secondary graft 
failure) at 2 8 -1 7 2  d (median 106). 173 patients engrafted 
with leucocytes 5= l - 0 x l 0 9/l at a median of 17d (range 
10-58) after BMT. The speed of engraftment did not differ 
between the patients who were conditioned with anthra­
cyclines at day —12 and —11 and the patients conditioned 
without anthracyclines. They engrafted at median 17 d 
(range 9 -3 5 ) and median 16 d (range 5 -5 8 ) after BMT, 
respectively. However, in patients conditioned with anthra­
cyclines from day - 7  to day - 2  engraftment was 
considerably delayed to a median of 20 d (range 8-37).
Acute GVHD
The characteristics of GVHD are summarized in Table II. 34/ 
173 (20%) patients at risk developed acute GVHD ^ grade 2.
Table II. Incidence of GVHD in patients conditioned with or without 
the addition of anthracyclines.
mm
Acute GVHD (n— 175)
Grade 0 
Grade 1 
Grade 2 
Grade 3 
Grade 4 
All patients 
Chronic GVHD (n= 152) 
None 
Limited 
Extensive 
A|| patients
No. (%) of patients
Conditioned with
mn  i t  ' ' <4il.'n>  w  ....... . ,i ,t i. , )« ,,
48 (42) 
39(34) 
22 (19)
2 (2)
3 (3) 
114 (100)
56 (55) 
31 (31) 
14 (14) 
101  (1 0 0 )
■ 1 ■
. .w .......... . ...  . . ..“I '■<? 'VI •<. .Vf
36 (59) 
18 (29) 
4 (7 )
3 (5)
0 (0)
61 (100)
\ I *
36 (71) 
12 (23)
3 (6)
51 (1 0 0 )
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GVHD grade 3 and 4 occurred in only 8/173 patients (5%), 
and included the two patients who did not receive GVHD 
prophylaxis after BMT. The probability of acute GVHD 
5= grade 2 at day 100 after BMT was 19% (95% confidence 
interval [Cl] 11-27%). Using multivariate analysis acute 
GVHD > grade 2 was significantly higher in the patients 
conditioned with anthracyclines (Odds 2-56; P =  0-024). 
Patients transplanted for AML had more acute GVHD 
5= grade 2 than ALL (Odds 2-27; P =  0*039) or CML (Odds 
2 ’63', P =  0*028) cases. We did not observe any significant 
relationship between T-cell dose in the marrow graft and 
acute GVHD.
after retransplantation and one patient died from sepsis 2 
years after second BMT. 25 patients (AML: n =  9; CML: 
n =  11: ALL: n =  5) who relapsed from their original disease 
were treated with lymphocyte infusions from the original 
marrow donor (Bar el al, 1993: Kolb et al, 1995). 11 patients 
(44%) responded (AML: 72 =  1; ALL: 72 =  1; CML: n =  9) and 
reached a second haematological and cytogenetic remission. 
They are without any sign of relapse at the end of follow-up. 
Two patients with a relapse from CML who did not respond 
to lymphocyte infusions were retransplanted with unmani­
pulated donor marrow and both are alive without leukaemia 
at 33 and 23 months after retransplantation.
Chronic GVHD
out of 152 patients (39%) with a follow-up of > 3 
s developed chronic GVHD. The 5-year probability of 
extensive chronic GVHD was 11% (95% Cl 5-17%).
in multivariate ant patients with a 
female donor developed less chronic GVHD than patients 
with a male donor (Odds 0 3 0 ; P =  0*0004). In contrast to 
acute GVHD, the risk for chronic GVHD increased with a 
relatively higher T-cell dose in the marrow graft (Odds 1*85; 
P = 0*039). No significant relationship was observed 
between intensification of the conditioning regimen by the 
addition of anthracylines and chronic GVHD, although the 
group treated with anthracyclines showed a trend to develop 
more chronic GVHD.
Mortality
Seventy-nine of 181 patients (44%) died after BMT. Principal 
causes of death were: relapse (n =  36), GVHD-related 
(72 =  24), infection (n =  8), acute respiratory distress syn­
drome/capillary leakage (77=5), secondary graft 
(71=  3), primary graft failure (72=  1), veno-occlusive disease 
(72=1) and bleeding (77 =  1). Transplant-related mortality 
censored by relapse was 22% in the patients conditioned 
with anthracyclines and was 26% in the patients condi­
tioned without anthracyclines. 54/181 patients (30%) died 
within a year after BMT. Mortality was transplant-related in 
39 patients and 15 patients died from relapse.
Forty-eight patients (27%) relapsed after BMT. The projected 
5-year probability of relapse was 39% (95% Cl 25-53% ) for 
AML-CR1, 32% (95% Cl 14-50%) for ALL-CR1,2 and 39% 
(95% Cl .13-65%) for CML-CP1. The projected 5-year 
probability of relapse in all patients treated with anthra-
2S was 26% (95% Cl 16-36%). This was significantly 
lower than the probability of relapse of 52% (95% Cl 3 8 -  
66%) in all patients conditioned without the addition of 
anthracyclines (P =  0*015). These relapse curves are shown 
in Fig 1A. Probabilities of relapse for patients treated with 
and without anthracyclines are summarized in Table III. In 
multivariate analysis relapse rates were significantly lower in 
patients conditioned with the addition of anthracyclines
(Odds 0*50: P =  0-044).
Two patients with relapse of CML were retransplanted 
after conditioning with 16 mg/kg busulphan alone without 
an attempt to induce CR with donor lymphocyte trans­
fusions. One patient died from subsequent relapse 17 months
Survival
One hundred and one of 181 patients (56%) were alive at 3 -  
166 months (median 63) after BMT, The projected 5-year 
probability of survival was 45% (95% Cl 32-58%) for AML- 
CR1, 54% (95% Cl 42-66% ) for ALL-CR 1,2 and 70% (95% 
Cl 62-78% ) for CML-CP1. The projected 5-year probability 
of survival in all patients conditioned with anthracyclines 
was 62% (95% Cl 52—72%). This was significantly better 
than the 44% (95% Cl 33-55%) obtained in all patients 
conditioned without anthracyclines (P =  0*01) (Fig IB). 
Using multivariate analysis, survival was significantly better 
in those patients conditioned with anthracyclines compared 
to patients treated with cyclophosphamide and TBI only 
(Relative Risk 0*63, 95% Cl 0*41-0-99%; P =  0-044). 
Probabilities of survival for patients treated with and without 
anthracyclines are summarized in Table III.
Leukaemia-free survival
The projected 5-year probability of LFS after T-cell-depleted 
BMT was 44% (95% Cl 31-57% ) for AML-CR1, 53% (95% 
Cl 41-65% ) for ALL-CR 1,2 and 48% (95% Cl 34-62%) for 
CML-CP1. The projected 5-year probability of LFS in all 
patients conditioned with anthracyclines was 56% (95% Cl 
46-66% ). This is significantly better than the 36% (95% Cl 
25-47% ) probability of LFS obtained in all 
conditioned without anthracyclines (P =  0*004) (Fig 1C). 
In multivariate analysis LFS was significantly better after 
conditioning with anthracyclines (Relative Risk 0-62, 95% 
Cl 0*41-0*94%; P =  0*02 5 ). Probabilities of LFS for patients 
treated with and without anthracyclines are given in Table 
III. Increased survival and LFS can be explained by the 
significantly lower relapse in patients treated with anthra­
cyclines (probability of relapse: Odds ratio 0*50; P =  0*044). 
Projected at 5 years, probability of relapse, survival, and 
leukaemia-free survival for all patients conditioned with and 
without anthracyclines are summarized in Table III.
?tic chi mam
Haemopoietic chimaerism was assessed at 6 and 12 months 
after BMT. Methods used were red blood cell phenotyping 
and cytogenetic analysis of bone marrow metaphases as 
described previously (Schattenberg et al 1989). At 6 and 12 
months after BMT, respectively, 131 and 100 patients were 
in complete remission. 19 patients had no discriminating 
marker at 6 months after BMT and 14 patients had no 
discriminating marker at 12 months after BMT. They were 
excluded from further analysis. If at one time point there was
© 1997 Blackwell Science Ltd, British Journal of Haematology 98: 750-759
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Fig 1 A. Probability of relapse in standard-risk 
patients (AML-CR1, ALL-CR 1,2 and CML-CP1) 
conditioned with and without anthracyclines 
(anthra). Marks in the relapse curves denote 
leukaemia-free survivors
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Fig IB. Probability of leukaemia-free survival 
in standard-risk patients (AML-CR1, ALL- 
CR1,2 and CML-CP1) conditioned with and 
without the addition of anthracyclines 
(anthra). Marks in the curves indicate 
leukaemia-free survivors.
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Fig 1C. Probability of survival in standard-risk 
patients (AML-CR1, ALL-CR 1,2 and CML-CP1) 
conditioned with and without anthracyclines 
(anthra). Marks denote patients who are alive.
disagreement between the results obtained by cytogenetic 
analysis and those obtained by red blood cell phenotyping 
and one of these methods showed mixed chimaerism, 
patients were considered to be mixed chimaera. The results
The influence of chimaerism status at either 6 or 12 
months on subsequent relapse is demonstrated in Figs 2A 
and 2B. The 5-year probability of relapse in patients who 
were mixed chimaera at 6 months after BMT did not differ 
significantly from patients who were donor chimaera at 6
© 1997 Blackwell Science Ltd, British Journal of Haematology 98: 750-759
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Table HI. Projected 5-year-probability of survival, leukaemia-free survival, relapse and P 
values in patients transplanted for AML-CR1, ALL-CR1.2, CML-CP1 and for patients 
conditioned with and without the addition of anthracyclines.
Per cent probability (95% confidence interval)
Survival Leukaemia-free survival Relapse
All patients 57 (51-63) 50 (43-57) 34 (24 -44)
No anthracyclines 4 4 (3 3 -5 5 ) 36 (25-47) 52 (38-66)
Anthracyclines 62 (52-72) 56 (46—66) 26 (16-36)
P =  0-010* P =  0-004* Pas 0*01 5*
AML-CR1 45 (32-58) 44 (31-57) 39 (25-53)
No anthracyclines 38 (15-61) 34 (10—58) 51 (29-73)
Anthracyclines 51 (36-66) 51 (34-68) 31 (13 -49)
P =  0*149* P =  0-053* P =  0-079*
ALL-CR1.2 54 (42-66) 53 (41-65) 32 (14 -50)
No anthracyclines 41 (16-66) 41 (21-61) 5 0 (2 7 -7 3 )
Anthracyclines 64 (52-76) 62 (44-70) 20 (4-36)
P =  0-094* P =  0-107* P -  0-020*
CML-CP1 70 (62-78) 48 (34-62) 39 (13-65)
No anthracyclines 64 (44—84) 36 (11-61) 5 5 (2 6 -8 4 )
Anthracyclines 72 (65-79) 55 (35-75) 31 (13-49)
P =  0-193* P =  0-063* P =  0-072*
* P value of differences in treatment outcome of patients conditioned with anthracyclines 
versus no anthracyclines using two-tailed Log Rank test.
0.6
0.4
0.2
0
0 24 48
Mixed chimeras
72 96 120
months
♦
Donor chimeras
1 44 168
Fig 2A. Probability of relapse in patients who 
were mixed chimaera and patients who were 
donor chimaera at 6 months after BMT. 
Marks denote patients who are alive,
0.6
0.4
0.2
0
0 24 48 72 96
months
Mixed chimeras
♦
p=0.004
Donor chimeras
♦
120 1 44 168
Fig 2B. Probability of relapse in patients who 
were mixed chimaera and patients who were 
donor chimaera at 12 months after BMT. 
Marks denote patients who are alive.
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Table IV. Chimaerism at 6 and 12 months after BMT using cytogenetic analysis and/or 
red blood cell phenotyping and 5-year probability of relapse in patients as a consequence 
of chimaerism at 6 and 12 months.
Chimaerism
6 months 12 months No. of patients
Donor chimaera Donor chimaera 30
Donor chimaera Mixed chimaera 6
Donor chimaera Died 5
Donor chimaera Relapse 2
Donor chimaera Follow-up < 12  months 7
Mixed chimaera Donor chimaera 18
Mixed chimaera Mixed chimaera 32
Mixed chimaera Died 1
Mixed chimaera Relapse 7
Mixed chimaera Follow-up < 12  months 3
Chimaerism 5-year probability of relapse
(% probability (95% coniidence
interval))
Donor chimaera, 6 months after BMT 33 (20-46)
Mixed chimaera, 6 months after BMT 29 (16-32)
P = 0-376*
Donor chimaera, 12 months after BMT 10 (0-18)
Mixed chimaera, 12 months after BMT 29 (14-34)
P =  0-004*
* P value of differences in relapse rate in patients who were donor chimaera and mixed 
chimaera at 6 and 12 months after BMT.
months after BMT (P =  0 3  76). However, patients who were 
mixed chimaera at 12 months after BMT were significantly 
more at risk to develop relapse of their original disease com­
pared to patients who were donor chimaera at 12 months 
after BMT (P =  0-004). In multivariate analysis the addition 
of anthracyclines to the conditioning regimen was the only 
significant factor contributing to a lower number of mixed
chimaeras in patients at 6 months (Odds 0-54; P — 0-027) 
and at 12 months (Odds 0-47; P =  0-032) after BMT.
Bone marrow transplantation with grafts of
lymphocytes is associated with a higher incidence of graft 
failure. Graft failure occurred in 2-20%  of HLA-identical 
T-cell-depleted sibling transplants compared to 0-2%  of 
recipients of HLA-identical unmanipulated bone marrow 
(Champlin, 1993; Goldman et al, 1988; Maraninchi et al,
& Aversa, 1993; Martin et al, 1985;
; Naparstek et al, 1995; O’Reilly, 
1992). In the present study graft failure occurred in 5% 
of cases which is less than previously reported in recipients 
of T-cell-depleted grafts (Bordignon et al, 1989; Champlin, 
1993; Kern.au et al, 1989; O’Reilly, 1992; Patterson et al, 
1986). Since residual autologous immunocompetent T
1987; Mar 
Mitsuyasu et al, 1
lymphocytes are responsible for graft rejection, the low 
incidence of graft failure in our patients may be caused by 
the number and nature of lymphocytes given within the 
graft, the relatively high midline average TBI dose rate and 
the addition of anthracyclines to the conditioning regimen.
T-cell depletion is an effective prevention of GVHD as has 
been shown in experimental animal models and in man 
(Marmont et al, 1991; Prentice et al, 1984; van Bekkum, 
1985). In the present analysis the probability of acute GVHD 
grade 2 at day 100 after BMT compares favourably with 
the actuarial incidence of 40 
identical unmanipulated
from
) in recipients of HLA- 
and is comparable with
marrow
(Apperley et al, .1986; Butturini & Gale, '1988; Goldman et 
al, 1988; Maraninchi et al, 1987; Marmont et al, 1991; 
Martelli & Aversa, 1993; Naparstek et al, 1995). The 
incidence of acute GVHD ^ grade 2 was significantly 
higher in the patients conditioned with anthracyclines and 
in patients with AML-CR1 compared to patients with ALL- 
CR1, CR2 or CML-CP1. The addition of anthracyclines to the 
conditioning regimen may eliminate more immunocompe­
tent autologous T lymphocytes. As a consequence the 
balance may be tipped to the relatively low number of 
donor T lymphocytes given within the graft, leading to more 
GVHD and GVHD associated graft-versus-leukaemia effect.
1997 Blackwell Science Ltd, British Journal of Haematology 98: 750-759
T-cell depleted BM T after Intensified Conditioning 757
In patients with AML-CR1 the higher cumulative dose of 
anthracyclines already used for remission and consolidation 
may have contributed to the increased probability of acute 
GVHD in this group of patients,
The 5-year probability of chronic GVHD and its extensive 
manifestation is in the same range of HLA-identical T-cell- 
depleted transplants in other studies (Blaise et al, 
Filipovich et al, 1982; Maraninchi et al, 1987; Marmont et al, 
.1991; Martelli & Aversa, 1993; Mitsuyasu et al, 1986; 
Naparstek et al, 1995; Prentice et al, 1984). In multivariate 
analysis we observed a relationship between the T-cell dose 
and the probability of developing chronic GVHD. Increasing 
the T-cell dose by only 1 ‘0 x 1  OfVkg body weight doubled the 
risk for chronic GVHD. Patients conditioned with anthra­
cyclines also developed more chronic GVHD, although this 
difference was not significant (P =  ()•()56). In contrast to 
other studies we observed a significantly lower incidence of 
chronic GVHD if the donor was female. At present we cannot 
explain this observation other than that this may have 
occurred by chance. Although the addition of anthracyclines 
to the conditioning regimen is correlated with significantly 
more acute GVHD > grade 2 and associated with a trend 
towards more chronic GVHD, no higher transplant-related 
mortality was observed in this group of patients.
Prevention of leukaemic relapse is the ultimate goal in 
allogeneic BMT. In general, T-cell depletion significantly 
reduces LFS after BMT and this is caused by higher relapse 
rates. LFS after T-cell-depleted BMT for leukaemia in CR1 or 
CPI varied from 48% at 2 years to 25% at 7 years (Blaise et 
al, 1993; Marmont et al, 1991; Naparstek et al, 1995). In 
standard-risk recipients of HLA-identical unmanipulated 
grafts, LFS varied from 70% at 2 years to 40% at 10 years 
(Blaise et al, 1993; Chao & Blume, 1990; Chao et al, 1991; 
Clift et al, 199 3; Goldman et al, 1988; Gratwohl et al, 1993; 
Marmont et al, 1991; Zhang et al, 1995; Zittoun et al, 1995). 
Recent cumulative clinical data from the International Bone 
Marrow Transplant Registry (IBMTR) showed a 2-year 
probability of relapse of 30% after transplantation with 
lymphocyte-depleted grafts for acute leukaemia in 
complete remission and 44% for chronic myeloid leukaemia 
in first chronic phase. These percentages were 17% and 
10%, respectively, in recipients of HLA-identical unmanipu­
lated transplants (Marmont et al, 1991). In the present study 
the intensification of the conditioning regimen with anthra­
cyclines in 116 patients increased 5-year LFS to between 
51% and 62%. In the patients conditioned with the addition 
of anthracyclines, the 5-year probability of relapse was 26% 
and compared favourably with the 3 7% at 2 years from the 
IBMTR (Marmont et al, 1991). In multivariate analysis, 
intensification of the conditioning regimen with anthra­
cyclines reduced the risk of relapse by 5 0% and was the only 
significant factor contributing to an increased probability of 
LFS. Using multivariate analysis, chemotherapy before 
allografting had no effect on the probability of engraftment, 
GVHD, mortality, relapse, survival and LFS after BMT. No 
other additional variables met the 0-05 significance level for 
entry in the statistical model. Anthracyclines, like other 
additional chemotherapeutics, may contribute to an 
increased eradication of the tumour burden especially in
CML and result in lower relapse rates (Feler et al, 1982; 
Martelli & Aversa, 1993). We have also shown that the 
addition of anthracyclines was correlated with increased 
probabilities of acute and chronic GVHD. This may have 
further enhanced the graft-versus-leukaemia effect.
Especially in patients with a relapse from CML after BMT, 
treatment with infusion of lymphocytes from the original 
marrow donor may induce second complete remission (Cullis 
et al, 1992; Drobyski et al, 1992; Kolb et al, 1990, 1995). 11 
patients who relapsed from CML-CP1 were treated with 
lymphocyte infusions from the donor and nine patients 
(82%) responded. If we correct our data for patients in first 
and second remission, the 5-year probability of LFS from T- 
cell-depleted BMT onward would increase from 48% (95% Cl 
34-62% ) to 67% (95% Cl 58-76%).
Using red blood cell phenotyping and cytogenetic analysis 
of the bone marrow, evaluation of chimaerism at 6 months 
and 1 year after BMT showed high incidences of mixed
chimaerism. T are comparable with
chimaerism studies after transplantation with T-cell-depleted
marrow grafts (Bertheas et al, Roy et al, 1990;
Schattenberg et al, 1989). In a previous analysis we showed 
that mixed chimaerism at 6 months after BMT was not 
correlated with higher incidence of relapse (Schattenberg
et al, 1990, 1989). The data in this study confirm this 
conclusion. However, if we evaluate the chimaerism status at 
12 months after BMT, mixed chimaerism is correlated with 
an increased probability of relapse. The differences in relapse 
rate may be explained by a relatively high number of patients 
who were still mixed chimaera at 6 months after BMT and 
changed to complete donor chimaera at 12 months after 
BMT. Another explanation may be selection of patients 
transplanted for CML. Patients transplanted for AML and 
ALL usually relapse early after BMT and progression to 
relapse is usually very rapid, resulting in a relatively higher 
number of observed donor chimaeras that relapse. Data in 
the literature concerning the influence of mixed chimaerism 
at one time point post-BMT on the risk of leukaemic relapse
(McCann & Lawler, 1993). Investigating 
chimaerism using serial analysis over time is essential in 
order to validate the significance of mixed chimaerism after 
BMT and is being assessed in an ongoing {
In the present analysis we show that BMT with grafts 
deleted of lymphocyes by counterflow c 
in low graft failure. Intensification of the c 
the addition of anthracyclines decreased relapse rate 
increas
are
probability of LFS. rJ data
favourably with other studies using T-cell depletion (Blaise 
et al, 1993; Bordignon et al, 1989; Champlin, 1993; Kernan 
et al, 1989; Marmont et al, ,1991; Naparstek et al, 1995; 
O’Reilly, 1992; Patterson et al, 1986). The probability of 
survival and LFS is equivalent to that reported in the 
literature for recipients of untreated grafts, but the morbidity 
due to GVHD is low. In patients transplanted for CML, relapse 
can be treated with donor lymphocytes. This may be very 
important for the future of T-cell-depleted BMT. In patients 
with AML and ALL further efforts should be made to reduce 
relapse rate. Adoptive immunotherapy by delayed or selected 
lymphocyte add-back after T-cell-depleted BMT in patients
© 1997 Blackwell Science Ltd, British Journal of Haematology 98: 750-759
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with a high probability of relapse is one of the possibilities 
currently under investigation.
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